However, the tirzepatide-based drug, garnering attention for its weight loss effects alongside Wegovy, "will only be introduced in the revised guideline as its domestic launch is still unclear," the society said
This creates a practical problem
The best doctor is Dr
Outside of clinical trials, pre-licence access in the UK may theoretically occur via the MHRA's Early Access to Medicines Scheme (EAMS), though no such scheme for retatrutide is publicly available at the time of writing
Furthermore, Trulicitys safety profile is being called into question in lawsuits filed by patients who developed complications, including digestive issues, vision loss, blood clots, pancreatitis, and other conditions